Evidence brief
SS-31 / Elamipretide: Mitochondrial research context and evidence limits
This brief separates mitochondria-focused laboratory research and defined clinical-study contexts from general health, performance, product, or personal-use claims. It does not provide treatment, administration, dosing, sourcing, or product-quality guidance.
Evidence maturity: early, disease-specific human trials and varied clinical research outcomes; not a general clinical-use conclusion.
Human evidence
The cited primary literature includes small randomized studies in defined primary mitochondrial myopathy and heart-failure research populations. Specific populations, short study windows, and limited sample sizes constrain interpretation and do not establish an outcome for other people, conditions, or product forms.
Preclinical context
A 2025 review describes elamipretide, also called SS-31, as a mitochondria-targeting tetrapeptide studied in relation to cardiolipin and mitochondrial bioenergetics. Laboratory and animal findings frame research questions; they are not clinical proof.
What remains unknown
Broader controlled human evidence, long-term safety characterization, durable clinical-outcome evidence, comparative research, and a general clinical indication are not established by the cited sources.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| early, disease-specific human trials and varied clinical research outcomes; not a general clinical-use conclusion. | The cited primary literature includes small randomized studies in defined primary mitochondrial myopathy and heart-failure research populations. Specific populations, short study windows, and limited sample sizes constrain interpretation and do not establish an outcome for other people, conditions, or product forms. | Broader controlled human evidence, long-term safety characterization, durable clinical-outcome evidence, comparative research, and a general clinical indication are not established by the cited sources. |
Canadian regulatory context
Health Canada’s Drug Product Database is an official search tool for products authorized for sale in Canada. This educational brief does not infer authorization, listing status, quality, availability, or suitability for any compound or product.
Evidence timeline
- 1
Laboratory research: cardiolipin and mitochondrial-bioenergetics questions explored
- 2
2017–2018: small randomized studies in defined disease-specific populations
- 3
Current: broader, long-term, and general clinical-use questions remain
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Elamipretide review (2025)
Review of structure, mitochondrial research context, clinical-study landscape, and remaining uncertainty.
- Primary mitochondrial myopathy randomized trial (2018)
Phase I/II randomized research in a defined adult primary mitochondrial myopathy population.
- Heart-failure randomized trial (2017)
Randomized research in a defined heart-failure-with-reduced-ejection-fraction population.
- Health Canada Drug Product Database
Official Canadian product-database search context; no status is inferred here.